Naples Global Advisors LLC Has $4.93 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Naples Global Advisors LLC boosted its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 0.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 80,843 shares of the biopharmaceutical company’s stock after buying an additional 334 shares during the period. Naples Global Advisors LLC’s holdings in Bristol-Myers Squibb were worth $4,931,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Pinney & Scofield Inc. acquired a new position in Bristol-Myers Squibb in the 4th quarter worth $25,000. Park Square Financial Group LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $26,000. Global Wealth Strategies & Associates boosted its position in shares of Bristol-Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 275 shares during the period. Transce3nd LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at approximately $28,000. Finally, Fairway Wealth LLC acquired a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $28,000. Institutional investors own 76.41% of the company’s stock.

Insider Buying and Selling

In related news, EVP Samit Hirawat bought 4,250 shares of the business’s stock in a transaction dated Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Stock Down 0.2%

Bristol-Myers Squibb stock opened at $48.01 on Thursday. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The stock has a market cap of $97.70 billion, a P/E ratio of -10.86, a P/E/G ratio of 2.07 and a beta of 0.39. The company’s 50-day moving average price is $49.82 and its two-hundred day moving average price is $55.19. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm’s quarterly revenue was down 5.6% on a year-over-year basis. During the same period in the previous year, the company posted ($4.40) EPS. As a group, analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Analysts Set New Price Targets

BMY has been the topic of a number of recent research reports. UBS Group lowered their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a report on Friday, April 11th. Argus raised shares of Bristol-Myers Squibb to a “hold” rating in a research report on Friday, April 25th. Cantor Fitzgerald restated a “neutral” rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $55.00 target price (down previously from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Finally, Wells Fargo & Company increased their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.